Futura Medical ( (GB:FUM) ) has issued an announcement.
Futura Medical has announced that Panmure Liberum will now act as the sole broker and continue as the Nominated Adviser for the company. This change is part of Futura’s strategic efforts to strengthen its market positioning and enhance its operational efficiency, potentially impacting its stakeholders positively by ensuring better financial advisory and brokerage services.
More about Futura Medical
Futura Medical plc is a consumer healthcare company specializing in the development and global commercialization of innovative sexual health products. Their core strength lies in research, development, and commercialization of topically delivered gel formulations, with their lead product, Eroxon, being a clinically proven treatment for Erectile Dysfunction (ED). The company addresses significant unmet needs in the ED market, with distribution partners in major markets such as the US and Europe.
YTD Price Performance: -70.05%
Average Trading Volume: 742,034
Technical Sentiment Signal: Buy
Current Market Cap: £28.26M
For an in-depth examination of FUM stock, go to TipRanks’ Stock Analysis page.